Transplant center directory

The Blood and Marrow Transplantation Program at the Morgan Stanley Children's Hospital of New York-Presbyterian is an international transplant center, specializing in the treatment of children and young adults. We are a FACT, COG, NMDP-accredited transplant program. The Adult Blood and Marrow transplant program at New York Presbyterian is accredited by the NMDP and FACT accredited for autologous and allogeneic transplantation. We have 18 bed state of the art inpatient unit which opened in April 2014. We specialize in treatment of adults with Multiple Myeloma, Amyloidosis, Leukemia, Lymphoma, Sickle Cell disease, and various other blood diseases.

This center has been performing allogeneic transplants since 1997 and has been an NMDP/Be The Match transplant center since May 2002.

Morgan Stanley Children's Hospital of New York

This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 48 patients.

The actual 1-year survival of these patients is 85.4%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 75.6% and 94.4%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

New York Presbyterian Hospital/Columbia University Medical Center

This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 53 patients.

The actual 1-year survival of these patients is 67.9%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 61.9% and 84.2%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

All diseases

Number of transplants by age reported from January 1, 2021 to December 31st, 2022 (includes marrow, PBSC and cord blood)

Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.